国产女人香蕉精品视频_国产精品乱人无码伦中文āv一级在线片_AV十八岁在线免费观看_精品成人免费国产_亚洲一区二区三区伊人_两个男生相恋的vlog_香蕉视频下载.apk_日韩一区二区高潮_亚洲日韩欧美内射姐弟_国产亚洲精品A在线观看下载

Bruce E. Johnson博士在國(guó)家癌癥研究所任職期間，擔(dān)任肺癌生物學(xué)科負(fù)責(zé)人。于1999年加入丹娜法伯癌癥研究中心，現(xiàn)任肺癌項(xiàng)目領(lǐng)頭人、臨床研究中心主任，哈佛大學(xué)醫(yī)學(xué)院教授。

2008-2013年任ASCO癌癥基金會(huì)轉(zhuǎn)化研究教授，2015年成為美國(guó)醫(yī)師協(xié)會(huì)會(huì)員，2012年成為美國(guó)臨床腫瘤學(xué)會(huì)會(huì)員。

【專(zhuān)長(zhǎng)領(lǐng)域】

肺癌、間皮瘤、胸腺瘤

【教育背景】

1979年，畢業(yè)于明尼蘇達(dá)大學(xué)醫(yī)學(xué)院，取得醫(yī)學(xué)博士學(xué)位

芝加哥大學(xué)醫(yī)院，完成內(nèi)科住院醫(yī)培訓(xùn)

國(guó)家癌癥研究所，完成藥學(xué)專(zhuān)科培訓(xùn)

【從醫(yī)榮譽(yù)】(摘選)

2010年美國(guó)癌癥研究協(xié)會(huì)科學(xué)獎(jiǎng)

2009年國(guó)際肺癌研究協(xié)會(huì)科學(xué)獎(jiǎng)

【學(xué)術(shù)著作】(摘選)

ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer. Johnson BE, Kabbinavar F, Fehrenbacher L, Hainsworth J, Kasubhai S, Kressel B, Lin CY, Marsland T, Patel T, Polikoff J, Rubin M, White L, Yang JC, Bowden C, Miller V. J Clin Oncol. 2013 Nov 1;31(31):3926-34. doi: 10.1200/JCO.2012.47.3983. Epub 2013 Oct 7.

ATLAS：晚期非小細(xì)胞肺癌患者一線化療+貝伐單抗治療結(jié)束后，使用貝伐單抗伴或不伴厄洛替尼的療效對(duì)比，一項(xiàng)隨機(jī)、雙盲、安慰劑對(duì)照的IIIB期試驗(yàn)。

Race, Poverty, and Initial Implementation of Precision Medicine for Lung Cancer. Kehl KL, Lathan CS, Johnson BE, Schrag D. J Natl Cancer Inst. 2018 Dec 20.

種族、經(jīng)濟(jì)情況與肺癌精準(zhǔn)治療的實(shí)施

Horn L, Bauml J, Forde PM, Davis KL, Myall NJ, Sasane M, Dalal A, Culver K, Wozniak AJ, Baik CS, Mutebi A, Zhang P, Wakelee HA, Johnson BE. Real-world treatment patterns and survival of patients with BRAF V600-mutated metastatic non-small cell lung cancer. Lung Cancer. 2019 Feb; 128:74-90.

BRAF V600突變轉(zhuǎn)移性非小細(xì)胞肺癌患者的現(xiàn)實(shí)治療模式和生存率

A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade. Cell. Jerby-Arnon L, Shah P, Cuoco MS, Rodman C, Su MJ, Melms JC, Leeson R, Kanodia A, Mei S, Lin JR, Wang S, Rabasha B, Liu D, Zhang G, Margolais C, Ashenberg O, Ott PA, Buchbinder EI, Haq R, Hodi FS, Boland GM, Sullivan RJ, Frederick DT, Miao B, Moll T, Flaherty KT, Herlyn M, Jenkins RW, Thummalapalli R, Kowalczyk MS, Ca?adas I, Schilling B, Cartwright ANR, Luoma AM, Malu S, Hwu P, Bernatchez C, Forget MA, Barbie DA, Shalek AK, Tirosh I, Sorger PK, Wucherpfennig K, Van Allen EM, Schadendorf D, Johnson BE, Rotem A, Rozenblatt-Rosen O, Garraway LA, Yoon CH, Izar B, Regev A. 2018 Nov 01; 175(4):984-997.e24.

一個(gè)癌癥細(xì)胞程序促進(jìn)T細(xì)胞排斥，改善檢查點(diǎn)抑制劑耐藥

Impact of BRAF Mutation Class on Disease Characteristics and Clinical Outcomes in BRAF-mutant Lung Cancer. Dagogo-Jack I, Martinez P, Yeap BY, Ambrogio C, Ferris LA, Lydon C, Nguyen T, Jessop NA, Iafrate AJ, Johnson BE, Lennerz JK, Shaw AT, Awad MM. Clin Cancer Res. 2019 Jan 01; 25(1):158-165.

BRAF突變類(lèi)型對(duì)BRAF突變肺癌患者的疾病特征和臨床結(jié)局的影響

A Phase I Trial of Surgical Resection and Intraoperative Hyperthermic Cisplatin and Gemcitabine for Pleural Mesothelioma. Burt BM, Richards WG, Lee HS, Bartel S, Dasilva MC, Gill RR, Jaklitsch MT, Johnson BE, Swanson SJ, Bueno R, Sugarbaker DJ. J Thorac Oncol. 2018 Sep; 13(9):1400-1409.

手術(shù)切除和術(shù)中順鉑和吉西他濱熱灌注治療胸膜間皮瘤的I期臨床試驗(yàn)